Jeremiah Bearss

Company: Biolexis Therapeutics

Job title: Chief Medical Officer

Bio:

Dr. Jeremiah Bearss is the Vice President of Clinical Development at Biolexis Therapeutics, where he leads the design and execution of early-phase clinical trials for innovative small-molecule therapies targeting metabolic indications. He completed his Internal Medicine residency at Mayo Clinic Hospital in Phoenix, AZ, earning multiple departmental awards for excellence in patient care.
Dr. Bearss holds an MD/PhD from the University of Arizona, where his research in oncogenic signaling and P-body dynamics contributed to the development of novel PIM kinase inhibitors. He brings extensive translational research experience from both academic and biotech settings, including previous roles at Montigen and Tolero Pharmaceuticals.

Seminars:

Integrating Exercise Mimetics for Mimicking Physical Activity Benefits to Boost Metabolic Rate for Healthier Weight Loss 12:40 pm

Mimicking endurance training effects for improving mitochondrial function to enhance fat oxidation for sustained energy expenditure Activating muscle signaling pathways for increased glucose uptake to improve insulin sensitivity for better metabolic control Developing pharmacological agents for stimulating exercise-induced gene expression to boost caloric burn for passive weight managementRead more

day: Day One

Panel Discussion: Assessing Functional Readouts & Optimal Muscle-to-Fat Ratio to Redefine Success in Obesity Care to Improve Drug Performance 1:10 pm

Analyzing the critical need for functional readouts and clinically relevant endpoints beyond weight on a scale to accurately measure and demonstrate the benefits of muscle preservation in obesity treatment • Discussing the scientific and clinical consensus on how much muscle loss is too much, focusing on the optimal muscle-tofat ratio to guide therapeutic development and…Read more

day: Day One